JP2017507145A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507145A5
JP2017507145A5 JP2016553402A JP2016553402A JP2017507145A5 JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5 JP 2016553402 A JP2016553402 A JP 2016553402A JP 2016553402 A JP2016553402 A JP 2016553402A JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5
Authority
JP
Japan
Prior art keywords
delivery system
substance delivery
matrix
polymeric material
anabolic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507145A (ja
JP6510547B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053645 external-priority patent/WO2015124739A1/en
Publication of JP2017507145A publication Critical patent/JP2017507145A/ja
Publication of JP2017507145A5 publication Critical patent/JP2017507145A5/ja
Application granted granted Critical
Publication of JP6510547B2 publication Critical patent/JP6510547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553402A 2014-02-20 2015-02-20 Fgf−18を含むインプラント Active JP6510547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000598 2014-02-20
EP14000598.4 2014-02-20
PCT/EP2015/053645 WO2015124739A1 (en) 2014-02-20 2015-02-20 Implant comprising fgf-18

Publications (3)

Publication Number Publication Date
JP2017507145A JP2017507145A (ja) 2017-03-16
JP2017507145A5 true JP2017507145A5 (enExample) 2018-02-22
JP6510547B2 JP6510547B2 (ja) 2019-05-08

Family

ID=50151086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553402A Active JP6510547B2 (ja) 2014-02-20 2015-02-20 Fgf−18を含むインプラント

Country Status (24)

Country Link
US (1) US10086112B2 (enExample)
EP (1) EP3107592B1 (enExample)
JP (1) JP6510547B2 (enExample)
KR (1) KR102421950B1 (enExample)
CN (1) CN106232154A (enExample)
AR (1) AR099556A1 (enExample)
AU (1) AU2015220785B2 (enExample)
BR (1) BR112016018681B1 (enExample)
CA (1) CA2938796C (enExample)
DK (1) DK3107592T3 (enExample)
ES (1) ES2698117T3 (enExample)
HR (1) HRP20181573T1 (enExample)
IL (1) IL247106B (enExample)
LT (1) LT3107592T (enExample)
MX (1) MX368946B (enExample)
NZ (1) NZ723177A (enExample)
PL (1) PL3107592T3 (enExample)
PT (1) PT3107592T (enExample)
RS (1) RS58138B1 (enExample)
RU (1) RU2700414C2 (enExample)
SG (1) SG11201606697YA (enExample)
SI (1) SI3107592T1 (enExample)
WO (1) WO2015124739A1 (enExample)
ZA (1) ZA201605667B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507671A (ja) 2013-02-14 2016-03-10 ナノパレイル,エルエルシー 電界紡糸ナノファイバーのハイブリッドフェルト
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画
CA2971315C (en) 2015-01-29 2023-02-14 Ares Trading S.A. Immunoassays for high positively charged proteins
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
DK3688468T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CN117187255B (zh) * 2023-11-07 2024-01-30 北京大学第三医院(北京大学第三临床医学院) 编码FGF18或rhFGF18的mRNA及其在骨关节炎治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896825B1 (en) * 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
KR100380119B1 (ko) * 2001-04-19 2003-04-11 한국항공우주연구원 이원화된 통신속도 적응형 베이스 밴드 스위칭 위상시프트 키잉 장치
EP1273365A1 (fr) * 2001-07-06 2003-01-08 Recherche Et Developpement Du Groupe Cockerill Sambre Outils rotatifs pour le perçage en ligne de produits profiles
US20040136970A1 (en) 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
US8852240B2 (en) * 2004-10-25 2014-10-07 Kieran Murphy, Llc Methods and compositions for fostering and preserving bone growth
SI1828239T1 (sl) * 2004-12-10 2011-11-30 Zymogenetics Inc Proizvodnja fgf18 v prokariotskih gostiteljih
MY148277A (en) * 2006-08-25 2013-03-29 Ares Trading Sa Treatment of cartilage disorders with fgf-18
AU2010221089A1 (en) 2009-03-05 2011-09-15 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
US8431399B2 (en) 2010-03-02 2013-04-30 Taipei Medical University Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro
US10130687B2 (en) * 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
WO2012113812A1 (en) * 2011-02-22 2012-08-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nano-reservoirs technology for use in bone and/or cartilage regeneration
US9795714B2 (en) * 2013-12-24 2017-10-24 Ares Trading S.A. FGF-18 formulation in alginate/collagen hydrogels
BR112016018704B1 (pt) 2014-02-20 2021-01-05 Merck Patent Gmbh processo para produção de um material de cartilagem transplantável para engenharia de tecido
JP6431083B2 (ja) 2014-02-20 2018-11-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18化合物の投与計画

Similar Documents

Publication Publication Date Title
Haggerty et al. Biomaterials for revascularization and immunomodulation after spinal cord injury
RU2016137291A (ru) Имплантат, содержащий fgf-18
PH12018500162A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
JP2014139220A5 (enExample)
MX384527B (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
JP2017512194A5 (enExample)
JP2014221830A5 (enExample)
MY194018A (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2017507142A5 (enExample)
RU2016137292A (ru) Схема применения соединения fgf-18
JP2016517888A5 (enExample)
JP2017501140A5 (enExample)
JP2017522288A5 (enExample)
WO2021034958A3 (en) Materials for delivery of tetherable proteins in bone implants
JP2011528333A5 (enExample)
JP2018521643A5 (enExample)
JP2017519568A5 (enExample)
KR20120014251A (ko) 동종이식편의 접합을 개선하기 위한 생체활성 코팅 조성물 및 방법
HRP20180061T1 (hr) Indolkarbonitrili kao selektivni modulatori androgenskih receptora
NZ729628A (en) Methods for the treatment of peri-implantitis
JP2013520271A5 (enExample)
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
ME02644B (me) Novi preparati alfentanila za tretman akutnog bola
JP2020500930A5 (enExample)
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same